English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The plasminogen activator inhibitor type 1 (PAI-1) is the main inhibitor of tissue plasminogen activator and urokinase type plasminogen activator in the blood. Besides the key regulatory role in fibrinolysis, plasmin and its activators and inhibitors are responsible for the processes of extracellular matrix turnover and remodeling, cellular adhesion and migration, thus they participate in many pathophysiological processes such as thrombosis, fibrosis, atherosclerosis, cancer spread, and other. The measurement of PAI-1 expression and its levels is suggested for a risk factor assessment in certain diseases. Also, PAI-1 is being considered a potential therapeutic target that could modify disease development and progression. The aim of this work is to outline significant findings regarding PAI-1 application in diagnostics, risk factor assessment, and pathogenetic treatment of different diseases. Acta Medica Medianae 2018;57(2):106-112.

PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI - 1) AS A POTENTIAL DIAGNOSTIC AND THERAPEUTIC TARGET